CN1056082C - Anticancer drug - Google Patents
Anticancer drug Download PDFInfo
- Publication number
- CN1056082C CN1056082C CN94103448A CN94103448A CN1056082C CN 1056082 C CN1056082 C CN 1056082C CN 94103448 A CN94103448 A CN 94103448A CN 94103448 A CN94103448 A CN 94103448A CN 1056082 C CN1056082 C CN 1056082C
- Authority
- CN
- China
- Prior art keywords
- gram
- cancer
- anticarcinogen
- present
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a novel broad-spectrum composite type anticancer medical composition which discovers that single aromaticring ramifications have important anticancer activity and can be used as an antagonist. The present invention matches with small active peptide, metal and non-metallic complex compounds, other biological active materials and necessary secondary components to act on cancer cells through a plurality of antitumor mechanisms, and simultaneously, the present invention treats cancers synthetically by a method for improving the immunity of organisms. The present invention has the characteristics of high efficiency, broad spectrum and no toxic side effects. The present invention has hundreds of successful cases and off body cell experiment supports, and is novel promising anticancer medicine.
Description
The present invention proposes the compound anticarcinogen of a class, prescription relates to the component of several keys.
Making a general survey of the passing of world's cause of death can find, once accounting for dead first and second tuberculosis, pneumonia, tracheitis has sharply reduced because of the development of antibiotic medicine, once be the cerebrovascular disease of the maximum cause of the death, with the improvement of diet, the exploitation of good medicine has also reduced after the seventies.The not high cancer postwar mortality rate of death two prewar rises always; Become first cause of the death in many countries, and the trend of continuous rising is arranged, treatment for cancer is very urgent!
Reached an advanced stage by the invasion and attack of cancer cell, the pain that alleviate patient still is difficult to, and carries out surgical operation and radiotherapy method in order to treat cancer, and its injury is bigger.To infect other disease situation that causes death also a lot of because of the immunity degradation that causes patient, therefore will remove the feeling of terror of people to violent misery, need Drug therapy.Chemotherapy and immunotherapy are still that people hope.
Existing at present nearly hundred kinds of anticancer class chemicalses get the nod or enter clinical.Their classes are direct tumoricidal anticarcinogens, and another kind of is that the host is changed to the reaction of cancer, and self the strength treatment cancer that relies on the host i.e. (BBM) method.
Existing anticarcinogen has following a few class by its mechanism of action:
(1) alkylating agent: under normal physiological conditions, cause nucleic acid, the alkylating cell proliferation that influences of protein, and then kill cell.Comprise β-chloro thioether, tertiary aromatic amine, cyclophosphamide, ethylene amine, sulphonic acid ester, N-nitrosoureas etc.
(2) antagonist: have the normal substrate or the similar structure of coenzyme of enzyme, strive unexpectedly with normal substrate etc. in metabolic response, hinder the metabolic response of enzyme, medicine is mounted to and becomes aberrant nucleic acid among DNA or the RNA sometimes, destroys cell.Comprise antifol as (Methortexute), purine antagonist is as (6-Mercaphopuriue), pyrimidine antagonist (5-fluorouracil and derivant) etc.
(3) cancer-resisting substance of antitumor antibiotic class material and plant extract, existing tens of kinds.They all have extremely complicated chemical constitution.
(4) enzyme, hormone antagonist are as (steroid derivatives etc.).
(5) to have extremely strong anti-tumor activity be one of present widely used cancer therapy drug to antineoplastic platinum compounds (being cisplatin and derivant thereof), but kidney is had infringement and can suppress bone marrow.Produce very violent feeling sick, vomit.Therefore many pairs of few platinum chemical compounds of effect just are being synthesized and are being used for clinical.
(6) immune kind anti-cancer drugs (OK-32 etc.).
Because chemotherapy exists naturality and acquired resistance problem, has the branch problem of cancer, these have caused the multiformity and the inhomogeneity of cancer.Former position and metastasis site are not consistent to the susceptibility of medicine.Halmatogenesis in the cell proliferation process is the major reason (1cm that causes drug resistance and transfer
3The cancer piece just have 10
3Individual cell can make a variation) radical cure cancer basic principle be target to kill whole cancerous cell, even a cancerous cell survives also can take place again in theory.Therefore the difficulty of treatment of cancer is well imagined.Normally several anticarcinogens are used, are about to various independent active ingredients, the composition that mechanism of action is different reduces as far as possible and pays the cooperation of effect composition, and is aided with other complementary therapy and means, to alleviate the strong effect of paying.
Suitable medicine combines with corresponding therapy, makes that really some diseases are not treated, and Burkitt tumor, Wilm6 tumor, children's's lymph gemmule property leukemia, neural bud swell, Huo Jijin disease etc. can have been cured; Breast carcinoma, lymph tumor, carcinoma of prostate, bone marrow tumor, small cell carcinoma of lung, the white blood of acute myeloid etc. also can prolong life, but muddled regret is many poor differentiated carcinomas, even nearly all occasion can be thought the effect of tumor minimizing is arranged, but still can not look to prolonging life, chronic lymphocytic leukemia, ovarian cancer, gastric cancer, carcinoma of endometrium still are difficult to treatment, and small cell carcinoma of lung, colorectal cancer, pancreas cancer, cervical cancer, bladder cancer, adrenal gland cancer, renal carcinoma etc. still belong to the cancer that can not cure.
Mostly existing anticarcinogen is cytotoxic substance, and its toxic and side effects is very big, and the scope of application is limited.
Develop that anticancer effectiveness is strong, toxic and side effects is little, can cure the anticarcinogen of multiple cancer, just the target painstakingly pursued over several years of present inventors.
It is remarkable that purpose of the present invention is developed a kind of anticancer effect exactly, and toxic and side effects is little, wide spectrum, no addiction and the anticarcinogen that can conveniently make, and this obviously needs new thinking and based on the clinical medical achievement in modern times.Key problem in technology of the present invention is to filter out that the brand-new anticarcinogen composition of 1-2 kind is mixed with efficiently, wide spectrum, anticarcinogen that toxic and side effects is little.We notice that the benzopyrene of strong carcinogenecity has the height symmetrical structure, and we think that good anticarcinogen also should have the symmetry and the rigidity of height; Rotten careless toxin is that a kind of toxicity is very little, and the anticarcinogen that clinical result of use is good, there is the structure of insertable dna in it and can produces the active oxygen that the DNA chain is cut off, and can with the coordinate structure of ferrous iron, the structure of this insertable dna and metal chelating agent, the existence of metal ion and the structure of the dissection of DNA just interrelated with its active anticancer, this is the important references that we design anticarcinogen.Increasing of interior free yl is a major reason of canceration, and the harm of removing interior free yl is an importance of control cancer.Up-to-date studies show that glutathion (reduced form), Monohydrated selenium dioxide salt show active anticancer really, and they may be to work by catching interior free yl or removing activity in vivo oxygen and regulate the matrix immunologic function.Various independent good effects, the active ingredient that toxic and side effects is low, the different component of mechanism of action cooperatively interact and have better effect, should be able to pass cell and enter the canceration position in order to bring into play efficacy of a drug medicine, therefore need some active carriers and some biochemical activity material.In addition, main pharmaceutical compositions should have quite stable, is difficult for degraded in the presence of gastric acid and multiple gastric enzyme.Based on the achievement in research that above-mentioned thought and molecular biosciences study medicine, we have invented a kind of comparatively ideal compound anticarcinogen through screening for many years---the inventor be called " An Tuo can gold " (Antuokejin, ATKJ).
Content of the present invention is about a kind of compound anticarcinogen, comprises following component:
1.1 the antagonist of 0.1～80% weight percentage, general structure is:
R
1, R
2And R
3Be that carbon number is C
1～C
6Alkyl, C
3～C
6Cycloalkyl or H;
R
1With R
2And R
3Be can be different, but R
1With R
2And R
3Identical; R
1With R
2And R
3Can be all different; X and NO
2, NH
2, NO, SO
3H, NH
2OH;
1.2 the aminoacid of 0.1～10% weight percentage and reduced glutathion,
1.3 the platinum of 0.01～10% weight percentage, the aminoacid of ferrum, peptide complex and sodium selenite;
1.4 vitamin C and vitamin E, pollen and pharmaceutical adjuvant commonly used are an amount of.
Preferably following scheme: (a) 20～60% the 4-tert-butyl group-2,6-dimethyl-Nitrobenzol; (b) 1～5% reduced glutathion; (c) 2～10% sodium selenite; (d) aminoacid of 1～5% platinum, reduced glutathion complex; (e) vitamin C and vitamin E, pollen and pharmaceutical adjuvant commonly used are an amount of.
During preparation, with mentioned component porphyrize mixing, fill becomes capsule, is oral medicine of the present invention---and " An Tuo can be golden ".
The present composition can adopt conventional pharmaceutical dosage forms and conventional diluent or carrier to prepare these preparations, and the example of described diluent or carrier has: surfactant, lubricant, add and fill agent, thickening agent, binding agent, wetting agent, disintegrating agent.Representational dosage form has tablet, pilule, powder, Emulsion, granule, capsule, suppository, injection (solution, suspension etc.), as required, in pharmaceutical preparation, can at random mix coloring agent, antiseptic, spice, flavoring agent, sweetener and other medicines.
Experiment shows, R
1Be the big alkyl of spatial volume (tert-butyl group), R
3, R
2Be the less methyl of spatial volume, X shows significant anti-cancer activity, no obvious toxic and side effects when being nitro.This chemical compound has good spatial symmetry and rigidity, and have a strong polar group, suitable molecular size can insert in RNA and the DNA chain after it enters cancerous cell, and simultaneously institute's nitro of being with can form two hydrogen bond faces destruction RNA and dna structure with base, influences it and duplicates.The formation of simultaneously two hydrogen bonds also makes this associated complex comparatively stable, is difficult for dissociating, thereby reaches the purpose of control and final kill cancer cell.Chemical compound can act on the metabolic process of enzyme simultaneously, participates in striving unexpectedly of substrate, combines with the active site of some enzyme, thereby enzyme is lost activity, and final control cancer cell increases.Like this structure general regulations, poison is paid the discovery of the chemical compound that side effect is little, active anticancer is good, provides anticarcinogen synthetic new thought, may impel capturing and treat and new favourable turn occurring of cancer.
Described active small peptide can be reduced glutathion.Glutathion is one of most important bioactive substance of generally acknowledging at present, and it is regulating the human homergy, removes intravital active free radical, active oxygen, the aspect effect of enhancing body immunity and can not underestimate.Therefore it is another crucial composition of this cancer medicine, and its γ-amido link has quite stable to enzymolysis, is that it can enter appointed part and not deactivated major reason smoothly.It not only can bring into play the biological function of self, also is metal ion killer's most important chelating agent and carrier simultaneously, and the synergism of it and metal ion can make the DNA of cancerous cell and RNA destructurized or be cut.
Slaine can be mineral acid or acylate; Metal ion can be Fe
++, Pt
++, chelating agent can be active small peptide, aminoacid.Fact proved that more and more metal ion can change the synergism of the activity of enzyme and aminoacid and peptide can destruction and cutting DNA and RNA, directly destroys basic substance---the nucleic acid and the albumen of cell, thereby can effect a radical cure cancer.
Vitamin, pollen and bioactive peptide etc. have been to remove interior free yl, adjusting physical function, the effect of enhancing human body immunity function.
Cooperatively interacting of above-mentioned multiple components, with different machining function cancerous cell, can be so that drug effect greatly improves and different cancers is produced curative effect.
This medicine has showed stem-winding therapeutic effect, its outstanding feature is wide spectrum, has no side effect, produce effects, cure rate height, several years experiment and hundreds of volunteers are taken, has better curative effect mostly, after taking this product, feel that generally appetite increase, pain relief, sleep increase, the cancer (the depancreatize cancer is outer) of early, middle and late phase cancer and different piece is all had the case of healing, the several Nian Weijian recurrences that have.Its feature also is instant effect, and development and transfer that can very fast control cancer reduce its cancer piece and disappear, and do not have addiction.End-stage patients' ascites of existing ascites also can reduce or disappear gradually.May become generation wide spectrum, efficient, anticarcinogen that toxic and side effects is little.
Hereinafter provide the embodiment and the clinical effectiveness of this anticarcinogen.Only just the present invention will be described for these embodiment and result, but not be intended to limit scope of the present invention.Embodiment 1 (1) 2,6-dimethyl-4-tert-butyl group Nitrobenzol (840 gram) (2) glutathion (10 gram) (3) platinum glycine complexes (1 gram), ferrum glycine complexes (1 gram) (4) glycerol fatty acid monoester (50 gram) (5) pollen (200 gram) (6) compound vitamin (10 gram) (7) sodium selenite (20 gram) (8) sodium bicarbonate (50 gram) embodiment 2 (1) 2,6-dimethyl-4-tert-butyl group Nitrobenzol (400 gram) (2) glutathion (20 gram) (3) platinum glycine complexes (1 gram), ferrum glycine complexes (1 gram) (4) glycerol fatty acid monoester (20 gram), sucrose ester (20 gram), sorbitol anhydride ester (20 gram) (5) pollen (200 gram) (6) compound vitamin (10 gram) (7) sodium selenite (20 gram) (8) sodium bicarbonate (50 gram) embodiment 3 (1) 2,6-dimethyl-4-tert-butyl group Nitrobenzol (1000 gram) (2) glutathion (10 gram) the various natural amino acid mixture of (3) platinum complex (1 gram), the various natural amino acid mixture of ferrum complex (1 gram) (4) glycerol fatty acid monoester (50 gram) (5) pollen (200 gram) (6) vitamin C (10 gram) (7) sodium selenite (20 gram) (8) sodium bicarbonate (50 gram) embodiment 4 (1) 2,6-dimethyl-4-tert-butyl group Nitrobenzol (500 gram) (2) glutathion (20 gram) (3) platinum glycine complexes (3 gram), ferrum glycine complexes (5 gram) (4) glycerol fatty acid monoester (50 gram) (5) pollen (200 gram) (6) vitamin E (10 gram) (7) potassium selenite (20 gram) (8) sodium bicarbonate (50 gram) embodiment 5 (1) 2,6-dimethyl-4-tert-butyl group Nitrobenzol (840 gram) (2) glutathion (10 gram) (3) platinum glycine complexes (1 gram), ferrum glycine complexes (1 gram) (4) compound enzyme powder (400 gram) (5) glycerol fatty acid monoester (50 gram) (6) pollen (200 gram) (7) compound vitamin (10 gram) (8) sodium selenite (20 gram) (9) sodium bicarbonate (50 gram) embodiment 6 (1) 2,6-dimethyl-4-tert-butyl group Nitrobenzol (800 gram) (2) glutathion (10 gram) (3) platinum glycine complexes (1 gram), ferrum glycine complexes (1 gram) (4) glycerol fatty acid monoester (50 gram) (5) pollen (200 gram) (6) compound vitamin (10 gram) (7) sodium selenite (20 gram) (8) sodium bicarbonate (50 gram) embodiment 7 (1) 2,6-dimethyl-4-tert-butyl group Nitrobenzol (840 gram) (2) glutathion (10 gram) (3) platinum glycine complexes (1 gram), ferrum glycine complexes (1 gram) (4) compound enzyme powder (400 gram) (5) glycerol fatty acid monoester (50 gram) (6) pollen (200 gram) (7) compound vitamin (10 gram) (8) sodium selenite (20 gram) (9) sodium bicarbonate (50 gram) embodiment 8 (1) 2,6-dimethyl-4-tert-butyl group Nitrobenzol (700 gram) (2) glutathion (10 gram) (3) platinum glycine complexes (2 gram), ferrum glycine complexes (1 gram) (4) glycerol fatty acid monoester (50 gram) (5) pollen (200 gram) (6) compound vitamin (10 gram) (7) sodium selenite (20 gram) (8) sodium bicarbonate (50 gram) embodiment 9 (1) 2,6-dimethyl-4-tert-butyl group Nitrobenzol (600 gram) (2) glutathion (10 gram) (3) platinum glycine complexes (1 gram), ferrum glycine complexes (1 gram) (4) glycerol fatty acid monoester (50 gram) (5) pollen (200 gram) (6) compound vitamin (10 gram) (7) sodium selenite (20 gram) (8) sodium bicarbonate (50 gram) embodiment 10 (1) 2,6-dimethyl-4-cyclohexyl Nitrobenzol (840 gram) (2) glutathion (10 gram) (3) platinum glycine complexes (1 gram), ferrum glycine complexes (1 gram) (4) glycerol fatty acid monoester (50 gram) (5) pollen (200 gram) (6) compound vitamin (10 gram) (7) sodium selenite (20 gram) (8) sodium bicarbonate (50 gram)
Embodiment 11
(1) 2,6-dimethyl-3-acetyl group-4-tert-butyl group Nitrobenzol (800 gram)
(2) glutathion (10 gram)
(3) platinum glycine complexes (1 gram), ferrum glycine complexes (1 gram)
(4) glycerol fatty acid monoester (50 gram)
(5) pollen (200 gram)
(6) compound vitamin (10 gram)
(7) sodium selenite (20 gram)
(8) sodium bicarbonate (50 gram)
Embodiment 12
(1) 2,6-dimethyl-4-tert-butyl group nitrobenzophenone azanol (500 gram)
(2) glutathion (10 gram)
(3) platinum glycine complexes (1 gram), ferrum glycine complexes (1 gram)
(4) glycerol fatty acid monoester (50 gram)
(5) pollen (200 gram)
(6) compound vitamin (10 gram)
(7) sodium selenite (20 gram)
(8) sodium bicarbonate (50 gram)
According to a conventional method the mixture of above-mentioned composition is packed into hard capsule and soft capsule can make capsule.
Experimental example 1. is pressed the anticarcinogen of the described component preparation of embodiment 1, the inventor be called " An Tuo can gold " (Antuokejin, ATKJ) acute, long term toxicity, three genicity tests result are as follows:
The oral acute experiment of limiting the quantity of of An Tuokejin (ATKJ) mice shows that toxicity is extremely low, is difficult to look for fatal dose.The medicinal 2% soluble starch paste of powder stock is made into 40% (g/v) Cmax suspension, measures oral maximum administration volume peace Tuo Kejin (ATKJ) the chmice acute toxic reaction.With two groups of male and female, every group each 10, maximum is limited the quantity of respectively, and (dosage is movable diet situation and the death condition that 20g/kg (administration at twice) observes animal to volume filling stomach for i, g) administration.Continuous seven days observed result shows that the part Mus is taken medicine had jitter in back 20 minutes, and remission about two hours promptly recovers normal thereafter, does not see death.Therefore, An Tuo can gold to the oral LD50 value of mice greater than 20g/kg.
The oral peace holder of rat can golden trimestral long term toxicity test: be the safety of estimating peace Tuo Kejin, observe successive administration and after three months the body master is given birth to the reversibility that reaction and the order of severity thereof provide anti-target organ of toxicity and infringement thereof, determine nontoxic amounts of reactants, providing reference for drafting the human safe dose, is that the oral peace holder of rat can golden trimestral long term toxicity test result below.LD50＞20g/kg is reference with the test of anxious toxigenicity, gives the rat can golden continuous oral 90 days in the 6g/kg that limits the quantity of (take 12 of the complete approximately capsules of 3.6g every day with 60kg people, be equivalent to 100 times of human dosage) An Tuo.The medicine preparation, administering mode is with anxious poison experiment, the dosage 6.0g/kg An Tuokejin that limits the quantity of is roughly equal to 40% (g/v) suspension 15ml that 2% soluble starch liquid and medicated powder are made into, be administered once every day, per six times, surveys body weight weekly once, and carry out dosage at a high speed according to body weight, 12 weeks of continuous oral, observed again for 2 weeks after the drug withdrawal, the result shows:
1, clinical observation show rat continuously clothes do not see Non Apparent Abnormalities such as death, hair, activity, stool in 90 days.Administration group in most cases appetite increases, and weight increase is very fast, but with blank group difference little (P＞0.05).Illustrate that peace Tuo Kejin has no adverse effects to the general situation of rat.
2, hematological examination and blood biochemical check: respectively administration 90 days and drug withdrawal 14 days, the eyeball blood sampling is carried out above-mentioned check and is shown, red white corpuscle number, content of hemoglobin and classification, platelet do not have between group obviously poor (p＞0.05) all in range of normal value: all do not have significant difference (P＞0.05) between blood urea nitrogen (BUN), glutamate pyruvate transaminase (GPT), each group of three indexs of glutamic oxaloacetic transaminase, GOT (GOT).
3, pathologic finding: animal is put to death the part animal in administration after 90 days, measure the main organs coefficient results and find that the increase of administration treated animal liver weight is higher than the blank group, but its organ coefficient value is in range of normal value, and other organ coefficient value there is no unusually.
4, tissue slice: all animal hearts, liver, spleen, lung, kidney, stomach, duodenum, ovary, testis, prostate, adrenal gland, thyroid etc. are carried out histological examination, administration group liver, spleen, have hyperemia in various degree, edema, jenny obvious than buck, other internal organs are not seen drug-induced organic disease.
An Tuokejin teratogenesis toxicity test: test peace Tuo Kejin more helps illustrating the teratogenesis toxicity of peace Tuo Kejin to the teratogenesis that the is subjected to pregnant rat toxic action its sensitive period (becoming pregnant 7-17 days).With rat from day of looking into sperm for becoming pregnant the 0th day, the taking-up of will becoming pregnant, sub-cage rearing is divided into five groups at random, divides to be in addition, An Tuo can gold (ATKJ) 2g/kg group; The 1g/kg group; 0.5g/kg blank group aspirin (ASP) the 0.2g/kg positive controls of group and 2% starch, in the 7-17 days successive administrations of becoming pregnant, once a day, increase the timely dosage of adjusting to becoming pregnant 20 days in the filling of 1ml/100g ratio and with body weight, put to death with the cervical vertebra method that fractures, laparotomy inspection corpus luteum number immediately, the implantation number, absorb tire number (early absorb tire and absorb tire late period), the stillborn fetus number, the body weight of the tire number alive and the tire of living, height, tail is long, sex, Placenta Hominis is heavy, and observation has or not outward appearance unusual, then, 1/2 tire Mus alive is fixed in BouinShi liquid, to do the internal organs inspection, 1/2 is fixed in the ethanol in addition, wants color through alizarin, after glycerol is transparent, do the skeleton inspection, the gained data are checked with t, and statistical procedures is carried out in u-test and f check.
The result shows the average weight growth pattern of pregnant Mus, there is not significant difference between five groups, illustrate that peace Tuo Kejin occurs in the no maternal toxicity of this dosage range (0.5-2g/kg), fetal development also there is not influence, and the absorption tire rate of ASP group, apparently higher than reference group (P＜0.001), its fetal toxicity is apparent.Therefore in An Tuo can golden 0.5-2.0g/kg dosage range, be subjected to pregnant rat not have fetal toxicity and teratogenesis toxic action.
An Tuokejin causes and becomes prominent (micronucleus) experiment: the purebred male mice of NIH is divided into five groups at random, and (6/group) first group are the blank group, every mouse stomach 0.5ml 2% starch solution; Second group of positive matched group gives 60mg/kg cyclophosphamide (CP) intraperitoneal injection; The 3rd group is high dose group, gives 5g/kgATKJ; The 4th group is middle dosage group, gives 2.5g/kgATKJ; The 5th group is low agent snail group, gives 1.25g/kgATKJ; 3rd, the stomach single administration is irritated in 4,5 groups of all 2% starch solution suspensions of ATKJ.Put to death mice in 24 hours after the administration, clip one side femur, extracting marrow cell is made bone marrow smear by preceding method, fixing, dyeing, microscopy, 6 mices of each combined lens, every mice is observed 1000 PCE, calculates micronuclear rates, does statistical procedures with the t check.
The result shows that peace Tuo Kejin group (5g/kg, 25g/kg, 25g/kg) micronuclei in mice generation permillage of three dosage (is respectively 1.50 ± 1.38,2.00 ± 1.79,1.83 ± 1.33) compare difference that there are no significant (P＞0.05) with blank group (2.33 ± 1.03); And compare with positive controls (53.33 ± 6.92), micronuclear rates is obviously much lower, and highly significant poor (p＜0.01) is all arranged.So An Tuo can not have the effect that the PCEMNR micronuclear rates increases of bringing out by gold.
The experiment of experimental example 2. isolated cells:
Normal cell is 100% survival when but the An Tuo gold concentration is 0.5mg/ml.But the existing nearly half of the lung carcinoma cell (LD that is killed under this concentration
50-0.5mg/ml) the LD of melanoma cell
50＜0.01mg/ml.But illustrate the selective kill cancer cell of peace holder gold utensil function and to little (the anxious malicious LD of Normocellular destruction
50＞20g/kg) (Nanjing University's school of life and health sciences experimental result).
The isolated experiment result in December in 1992 U.S. Columbia University's clinic study institute on the 8th cancer card research center is as follows:
The F1 cancerous cell when An Tuo can kill off during golden 320ug/ml substantially, is suppressed during for 40ug/ml to increase.
Major part was killed when the C8161 cancerous cell can goldenly be 160ug/ml as An Tuo, all killed during for 320ug/ml.
To the E cancerous cell, but when the An Tuo gold concentration is 40ug/ml, suppress to increase, almost kill full during for 160ug/ml, all kill during for 320ug/ml.
Experimental example 3. embodiment 1 described anticarcinogen oral capsule faces complete more case name year unit of typical case or address diagnosis Time of Administration cumulative volume observation of curative effect
Open other age * * the low differentiation of male 54 Beijing Aero-Space lungs squama 91.10 takes 1500 tumors by 4cm
2Φ disappears,
Three months Australia antigen sun of the senior engineer of portion cancer lymph metastasis are turned out cloudy.Cure
6 years, working properly.The week * * male 35 Hebei Zunhua foreign trade spermatogonium 92,3 takes in 2000 recurrence tumor 5cm Φ disappearance
The section chief of company slip five monthly Hus of postoperative recurrence * * Daxing County, male 61 Beijing medicine hepatocarcinoma 91,1 takes 1500 rights lobe of liver 4.6 * 3.16,
(four months 7.2 * 3.4cm tumors of B ultrasonic and CT are obvious for the material company manager
Diagnosis) absorbs improvement.The king * * women 65 Mudanjiang Cities retirement hepatocarcinoma, take late period 92.8 1500 liver left and right sides tumors 4.7 *
The workman (is critically ill, sends out three months, 3.1cm, medication 45 days
Burn) behind the 92.9 quiet notes, narrow down to 2.3 *
The plain 30mg 1.7cm of AT.92.11, mould
Stick with paste unclear (closing with interferon
Obvious with effect) Qi * * Mentougou, women 42 Beijing rectal cancer 92.5 takes 2000 tumors and disappeared by 4 * 4cm
Annotated in three months: every capsules nearly weighs 0.3g, and this case is assert through the expert.
No matter the above fact proves all that from isolated cells experiment, clinical effectiveness, toxicity, three genicity tests and to Normocellular breaking test conclusion " An Tuo can gold " be the effective anticarcinogen of a generation, and its theory and practice has science.Its prescription is that reasonably clinical effectiveness is significant.The release of An Tuokejin and further improving will be brought hope to curing cancer!
Claims (4)
1. compound anticarcinogen comprises following component:
(a) antagonist of 0.1～80% weight percentage, general structure is:
R
1, R
2And R
3Be that carbon number is C
1～C
6Alkyl, C
3～C
6Cycloalkyl or H;
R
1With R
2And R
3Can be different, but R
2And R
3Identical; R
1With R
2And R
3Can be all different; X is NO
2, NH
2, NO, SO
3H, NH
2OH;
(b) aminoacid of 0.1～10% weight percentage and reduced glutathion,
(c) aminoacid of the platinum of 0.01～10% weight percentage, ferrum, peptide complex and sodium selenite;
(d) vitamin C and vitamin E, pollen and pharmaceutical adjuvant commonly used are an amount of.
2. anticarcinogen as claimed in claim 1, wherein antagonist is the 4-tert-butyl group-2,6-dimethyl-Nitrobenzol.
3. anticarcinogen as claimed in claim 1, it comprises
(a) 20～60% the 4-tert-butyl group-2,6-dimethyl-Nitrobenzol;
(b) 1～5% reduced glutathion;
(c) 2～10% sodium selenite;
(d) aminoacid of 1～5% platinum, reduced glutathion complex;
(e) vitamin C and vitamin E, pollen and pharmaceutical adjuvant commonly used are an amount of.
4. anticarcinogen as claimed in claim 1, this anticarcinogen contains drug excipient commonly used in addition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94103448A CN1056082C (en) | 1994-04-08 | 1994-04-08 | Anticancer drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94103448A CN1056082C (en) | 1994-04-08 | 1994-04-08 | Anticancer drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1121832A CN1121832A (en) | 1996-05-08 |
| CN1056082C true CN1056082C (en) | 2000-09-06 |
Family
ID=5031075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94103448A Expired - Fee Related CN1056082C (en) | 1994-04-08 | 1994-04-08 | Anticancer drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1056082C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1193746C (en) * | 1999-11-05 | 2005-03-23 | 门特娃 | Substituted nitrobenzene derivative for medicine and other use |
| CN1101804C (en) * | 2000-04-29 | 2003-02-19 | 刘全志 | Pharmaceutical compound for killing cancer cells and pathogenic bacteria and prepn. method therefor |
| CN1273195C (en) * | 2004-10-25 | 2006-09-06 | 孙汉翔 | Carbonized pollen and its application for preparing medicine to treat cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087865A2 (en) * | 1982-03-01 | 1983-09-07 | Efamol Limited | Pharmaceutical composition |
| EP0493883A1 (en) * | 1990-11-30 | 1992-07-08 | Norsk Hydro A/S | Cyclic (hetero)acetals of nitro substituted benzaldehydes having anti-cancer activity |
-
1994
- 1994-04-08 CN CN94103448A patent/CN1056082C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087865A2 (en) * | 1982-03-01 | 1983-09-07 | Efamol Limited | Pharmaceutical composition |
| EP0493883A1 (en) * | 1990-11-30 | 1992-07-08 | Norsk Hydro A/S | Cyclic (hetero)acetals of nitro substituted benzaldehydes having anti-cancer activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1121832A (en) | 1996-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2242286T3 (en) | ARSENICO SULFIDE COMPOUNDS EXEMPT FROM ARSENICO OXIDE FOR THE TREATMENT OF HEMATOLOGICAL CANCERS. | |
| AU2001230977B2 (en) | Combinations for treating neoplasms | |
| CN100411628C (en) | Combination chemotherapy | |
| UA94924C2 (en) | Compositions of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer | |
| JPH06505231A (en) | Use of quinones in the treatment of cancer or AIDS | |
| KR950008767B1 (en) | Novel pharmacentical use of ebselen | |
| KR100456831B1 (en) | Anticancer drug composition containing salt of meta-arsenite | |
| CN1056082C (en) | Anticancer drug | |
| Heys et al. | Potentiation of the response to chemotherapy in patients with breast cancer by dietary supplementation with L-arginine: results of a randomised controlled trial. | |
| JP2004517961A (en) | Cancer treatment | |
| JPS6328045B2 (en) | ||
| CN101485665B (en) | Novel medical use of cucurbitacin | |
| CN1787814A (en) | Method for augmenting the antitumor activity of anti-cancer agents | |
| CN109662968A (en) | The liter white preparation of -5 α androstane hydride compounds of carbon loss containing A- and its application | |
| KR20140035974A (en) | Combined pharmaceutical compositions for the treatment of tumours | |
| CN102727867B (en) | Antineoplastic pharmaceutical composition and application thereof, kit and package | |
| CN111558045A (en) | Medicine composition for treating lung cancer | |
| CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
| CN1867344A (en) | Pharmaceutical composition comprising oxoplatin, the salts and derivatives thereof | |
| Bhavaraju et al. | Acute toxicity of concomitant treatment of chemoradiation with single agent cisplatin in patients with carcinoma of the cervix | |
| Gellhorn et al. | Neoplastic Diseases Medical Care in Advanced Cancer | |
| CN111407748B (en) | Application of tyrosol in preparation of medicine for treating brain glioma | |
| CN110237262B (en) | HFn method for loading platinum medicine and its product | |
| McNaught et al. | Effects of Sulfanilamide, Phenothiazine and Thionol in Experimental Trichinosis. | |
| RU2161034C1 (en) | Immunocorrecting proteoselenium agent and method of immunocorrection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Xingda Sci. System Co., Beijing City Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Xingda Sci. System Co., Beijing City Document name: Notification of Termination of Patent Right |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20000906 Termination date: 20110408 |